DIMA

DIMA:

Leading product AF-29 is in late preclinical stage. Superior IL-1 signaling inhibition efficacy and prolonged PK were confirmed in rodent models. IND application is expected in Q1/2026.

  • Dual targeting inflammatory receptor and cytokine
  • High production yield in stable CHO expression system
  • High homogeneity and stability
  • Improving efficacy by synergistic IL-1 signaling blockade
  • Decrease side effects by minimizing systemic IL-1 signaling inhibition 
  • More efficacious than approved IL-1 neutralizing drugs
  • Broad inflammatory disease indications: inflammatory disease (such as severe and recurring goat and osteoarthritis), cancers and IL-1 relevant rare disease
Scroll to Top